Marksans Pharma has entered into a Business Transfer Agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations in Goa. The company plans to manufacture tablets, hard and soft gel capsules, ointments, gummies, and creams from the new capacity.

Marksans Pharma Ltd. is trading above its 200 day SMA of 227.9

Marksans Pharma Ltd.

21 Oct 2022

325.60

1.02%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Ventura

Growth visibility with reasonable valuation

Number of FII/FPI investors increased from 145 to 162 in Jun 2026 qtr.

Marksans Pharma Ltd.

06 Jun 2022

325.60

1.02%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Target

Arihant Capital

Marksans Pharma Ltd. is trading below its 30 day SMA of 328.4

Marksans Pharma Ltd.

14 Oct 2021

325.60

1.02%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Arihant Capital

We had hosted Investor Conference on 29th & 30th September 2021 where 15 companies participated at our Arihant Rising Star's Virtual Summit. Key takeaways from the conference are as follows:...

Number of FII/FPI investors increased from 145 to 162 in Jun 2026 qtr.

Marksans Pharma Ltd.

11 Jun 2018

325.60

1.02%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Source: Bloomberg, Centrum Research, *as on 8th June 2018 Recommendation and key risks: We have revised our FY19E and FY20E EPS downwards by 41% and 43% respectively. We downgrade MPL to Hold from Buy rating, with a TP of Rs31 based on 18x March'20E EPS of Rs1.7, and a 10.2%% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA...